Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Daratumumab vs Active Monitoring in High-Risk Smoldering Multiple Myeloma
NCT03301220Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2017
- Primary completion
- May 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 24
01
Overview
A Phase 3 trial of daratumumab in smoldering multiple myeloma (SMM), sponsored by Janssen Pharmaceutical. Started Nov 2017; status: completed.
02
Drugs
daratumumab
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT03301220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03301220.